Scilex Holding Company announced that it has entered into an agreement with a pharmacy chain in the U.S. to stock ELYXYB® in over 500 stores which do not currently stock ELYXYB®. Scilex is also in the process of negotiating similar potential stocking arrangements with other major pharmacy chains in the U.S. Clinicians in a recent market research study expressed their desire for fast and safe alternatives for two large pools of acute migraine patients ? those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use.

ELYXYB?s product profile mapped with a high degree of certainty to these stated unmet needs. In clinical studies, patients treated with ELYXYB® demonstrated pain relief in as little as 15 minutes, and significant pain relief compared to placebo within 45 minutes in approximately 50% of patients.